|
gptkbp:instanceOf
|
gptkb:Controlled_substance_schedule
|
|
gptkbp:administeredBy
|
gptkb:Drug_Enforcement_Administration
|
|
gptkbp:country
|
gptkb:United_States
|
|
gptkbp:criteria
|
Currently accepted medical use in treatment in the United States
Low potential for abuse relative to Schedule IV
Abuse may lead to limited physical or psychological dependence relative to Schedule IV
|
|
gptkbp:enactedBy
|
gptkb:United_States_Congress
|
|
gptkbp:example
|
gptkb:Lomotil
gptkb:Motofen
gptkb:Parepectolin
gptkb:Lyrica
Cough preparations with less than 200 mg of codeine per 100 ml or per 100 g
|
|
gptkbp:legalStatus
|
Prescription only
|
|
gptkbp:partOf
|
gptkb:Controlled_Substances_Act
|
|
gptkbp:regulates
|
Controlled substances
Analgesic drugs
Antidiarrheal drugs
Antitussive drugs
|
|
gptkbp:relatedTo
|
gptkb:Schedule_III_(US)
gptkb:Schedule_I_(US)
gptkb:Schedule_II_(US)
Schedule IV (US)
|
|
gptkbp:startDate
|
1970
|
|
gptkbp:bfsParent
|
gptkb:Lomotil
gptkb:Schedule_III_(US)
gptkb:pregabalin
gptkb:Lyrica
gptkb:Schedule_I_(US)
|
|
gptkbp:bfsLayer
|
7
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Schedule V (US)
|